Key Insights

Highlights

Success Rate

85% trial completion

Published Results

41 trials with published results (18%)

Research Maturity

104 completed trials (46% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

7.9%

18 terminated out of 227 trials

Success Rate

85.2%

-1.3% vs benchmark

Late-Stage Pipeline

13%

29 trials in Phase 3/4

Results Transparency

39%

41 of 104 completed with results

Key Signals

41 with results85% success18 terminated

Data Visualizations

Phase Distribution

174Total
Not Applicable (23)
Early P 1 (4)
P 1 (59)
P 2 (59)
P 3 (21)
P 4 (8)

Trial Status

Completed104
Unknown42
Recruiting33
Terminated18
Active Not Recruiting12
Withdrawn10

Trial Success Rate

85.2%

Benchmark: 86.5%

Based on 104 completed trials

Clinical Trials (227)

Showing 20 of 20 trials
NCT07574541Phase 2Not Yet Recruiting

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT07489066Phase 2RecruitingPrimary

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT06022757Phase 1TerminatedPrimary

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

NCT00027326Enrolling By InvitationPrimary

Collection of Blood and Urine From Patients Undergoing Radiation Therapy

NCT03091192Phase 3Active Not RecruitingPrimary

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT07257094RecruitingPrimary

Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer

NCT03208374Active Not Recruiting

Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling

NCT06630273Not Yet RecruitingPrimary

Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics

NCT04962958Phase 2CompletedPrimary

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

NCT05708950Phase 1Completed

A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

NCT03331601Phase 2TerminatedPrimary

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

NCT04897321Phase 1Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT07587814Not ApplicableNot Yet RecruitingPrimary

Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy

NCT06445114Phase 2Recruiting

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

NCT03857620Not ApplicableActive Not Recruiting

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

NCT07365124Not Yet RecruitingPrimary

MRinRT: Swansea University and SWWCC Collaboration Study.

NCT06456411Not ApplicableTerminated

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

NCT04483778Phase 1Active Not Recruiting

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT03778229Phase 2Active Not RecruitingPrimary

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT05559879Phase 1Recruiting

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Scroll to load more

Research Network

Activity Timeline